Shares in Align Technology do not show any sign of a slowdown in the ascending dynamic. Investors could bet on a continuation of the underlying trend. Investors have an opportunity to buy the stock and target the $ 239.
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Align Technology accounts for 4.33 % of our USA Portfolio. A trade is currently open since 08/01/2019 with a purchase price of $ 206.40. Discover the other 19 stocks of the USA portfolio managed by the MarketScreener portfolio management team.
The current area is a good opportunity for investors interested in buying the stock in a mid or long-term perspective. Indeed, the share is moving closer to its lower bound at USD 186.71 USD in weekly data.
Graphically speaking, the timing seems perfect for purchasing the stock close to the USD 157.26 support.
The prospective high growth for the next fiscal years is among the main assets of the company
The company returns high margins, thereby supporting business profitability.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Historically, the company has been releasing figures that are above expectations.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Based on current prices, the company has particularly high valuation levels.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 34.74 times its estimated earnings per share for the ongoing year.
Revenue estimates are regularly revised downwards for the current and coming years.
Subsector Medical Equipment, Supplies & Distribution - NEC
The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.